Pricing, reimbursement and access
Refine Search
Pharmaceutical
US President Donald Trump issued an executive order on April 15 listing several potential policy changes aimed at lowering US drug prices.
Responding to the announcement, Morningstar’s healthcare equity research director Karen Andersen gave her views on why this matters. 18 April 2025
Biotechnology
US mRNA specialist Moderna has announced that the German Standing Committee on Vaccination (STIKO) has issued a recommendation for mRESVIA, the company’s RSV vaccine available in a pre-filled syringe (PFS). 11 April 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Truqap (capivasertib) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. 11 April 2025
Pharmaceutical
The UK’s National Institute of Health and Care Excellence (NICE) has recommended erdafitinib, trade name Balversa and manufactured by Johnson & Johnson, for some adult patients in England. 10 April 2025
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (CER), in collaboration with researchers from Brown University, has published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications. 10 April 2025
Biosimilars
South Korea’s Samsung Bioepis presented data, including the budget impact analysis on ustekinumab biosimilars’ cost savings in Germany, the UK and Sweden at the 8th International Meeting on Intestinal Diseases in conjunction with the Annual Congress of the Korean Association for the Study of Intestinal Diseases (IMKASID 2025) held in Seoul, Korea. 10 April 2025
Generics
For more than four decades since the passage of the Hatch-Waxman Act, the US generic drug market has provided patients with low-cost alternatives to brand-name medicines, saving the health care system billions while preserving incentives for biopharmaceutical innovation. 9 April 2025
Pharmaceutical
Ireland’s government remains confident in its ability to retain the country’s strategic position in pharmaceutical manufacturing, despite rising tensions between the European Union and the United States over trade policy. 8 April 2025
Pharmaceutical
The USA’s Centers for Medicare & Medicaid Services (CMS) yesterday released the Calendar Year (CY) 2026 Rate Announcement for the Medicare Advantage (MA) and Medicare Part D Prescription Drug Programs that finalizes the payment policies for these programs. 8 April 2025
Pharmaceutical
The Chinese government is contemplating a new drug reimbursement category called category C to make commercial insurance companies a major payer. If the new category is introduced, it is expected to significantly accelerate China’s innovation, said speakers at the BIOCHINA event held in Suzhou. 5 April 2025
Biotechnology
Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, has announced that the National Institute for Health and Care Excellence (NICE) has issued its final guidance in England and Wales recommending the use of Altuvoct (efanesoctocog alfa). 2 April 2025
Generics
The Danish Medicines Agency's new analysis shows that generic prescribing will not necessarily lead to financial savings or increased patient safety. 31 March 2025
Pharmaceutical
The NHS Business Services Authority (NHSBSA) has released an exploratory analysis estimating that patients could have faced prescription charges totaling approximately £837 million ($1.1 billion) in the 2023/24 period without the use of prescription prepayment certificates. 26 March 2025
Pharmaceutical
A new report by the Wall Street Journal (WSJ) reveals abuse of the 340B hospital markup program is getting worse as hospitals and middlemen find new ways to profit off the program, according to a website posting by trade group Pharmaceutical Research and Manufacturers of America (PhRMA). 26 March 2025
Pharmaceutical
Interpharma has criticized Switzerland’s latest healthcare cost-cutting package, passed in a final parliamentary vote, noting that the legislation will imperil patient access and supply security. 24 March 2025
Pharmaceutical
Pharmaceutical leaders are warning that the UK is becoming an unattractive destination for investment due to high and unpredictable levies on medicine sales. 20 March 2025
Pharmaceutical
Budget limitations and health crises are a constant in several countries in the Americas, impacting not only the population, but also the pharmaceutical industry which, in some cases, does not benefit from solid regulatory bases to promote research or regulate innovative medicines, given that there are many cumbersome procedures and financial instability. 18 March 2025
Pharmaceutical
The UK has announced plans to abolish NHS England and integrate its functions into the central government, marking a significant shift in the nation's healthcare management. The restructuring aims to cut bureaucracy and enhance efficiency, resulting in approximately 10,000 job losses, with the anticipated savings redirected to frontline services. 14 March 2025
Pharmaceutical
An Expert View from Rob Abbott, chief executive and executive director of ISPOR — The Professional Society for Health Economics and Outcomes Research (HEOR), a nonprofit advancing HEOR excellence to improve decision-making for health globally. 10 March 2025
Pharmaceutical
The Bulgarian Association of Research-Based Pharmaceutical Manufacturers, ARPharM, says it is following the discussion of the National Health Insurance Fund (NHIF) budget for 2025 with attention and concern. 10 March 2025
Biosimilars
South Korea’s Samsung Bioepis has released its Third Quarter 2024 Biosimilar Market Report, which includes the latest Average Sales Price (ASP) information of all biosimilars and reference products available in the US market. 12 July 2024
Biotechnology
National Health Service (NHS) England has given approval to allow eligible patients access to Roche’s Ocrevus (ocrelizumab) subcutaneous injection for people with relapsing multiple sclerosis and primary progressive multiple sclerosis. 12 July 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the National Health Service (NHS) in England. 10 July 2024
Pharmaceutical
A new report from the USA's Federal Trade Commission (FTC) underlines how the agency regards middlemen as having the potential to inflate drug prices. 10 July 2024
Pharmaceutical
The Association of the British Pharmaceutical Industry (ABPI) has been quick to congratulate Keir Starmer and the Labour party on their victory in the UK general election. 5 July 2024
Pharmaceutical
A survey of British voters ahead of Thursday’s general election has revealed just how much importance they attach to the issue of access to medicines. 3 July 2024
Pharmaceutical
The US Department of Health and Human Services (HHS)—through the Centers for Medicare and Medicaid Services (CMS)—has announced that some Medicare enrollees will pay less for 64 drugs available through Medicare Part B. 27 June 2024
Biotechnology
The UK’s health technology assessor has changed its tune regarding CSL Behring’s Hemgenix (etranacogene dezaparvovec), recommending the product for use in England and Wales. 27 June 2024
Pharmaceutical
London-based pharma major GSK—one of the UK’s flagship companies—has suffered a galling defeat on home soil to US rival Pfizer. 25 June 2024
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has approved Crysvita (burosumab) from Japanese drugmaker Kyowa Kirin. 21 June 2024
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Eladynos (abaloparatide). 21 June 2024
Biotechnology
Sanofi today revealed that UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final draft guidance (FDG) not recommending Sarclisa (isatuximab) plus pomalidomide and dexamethasone (Isa-Pd), within its marketing authorization 20 June 2024
Pharmaceutical
Johnson & Johnson says it has “grave concern” for the availability of future innovative mental health treatments in England, following a decision by National Institute for Health and Care Excellence (NICE) to not re-appraise Spravato (esketamine nasal spray) for treatment-resistant depression in England 13 June 2024
Pharmaceutical
US Senator Bernie Sanders, chairman of the Senate Committee on Health, Education, Labor and Pensions (HELP), has announced that members will vote next week on whether to subpoena Doug Langa, senior vice president, head of North America operations and president of Novo Nordisk. 12 June 2024
Pharmaceutical
Russia is sharply cutting centralized state purchases of anti-HIV drugs due to the problems with funding and the reduction of supplies to Russia by global drugmakers, reports The Pharma Letter’s local correspondent. 12 June 2024
Biosimilars
As more biologics drugs lose their patent protection, the influx of biosimilars is set to expand, offering cost-effective alternatives and significantly impacting their respective markets. 5 June 2024
Pharmaceutical
Last week, the US Court of Appeals for the District of Columbia (DC) ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program, noted Sophia Gaulkin and Alan Kirschenbaum of law firm Hyman Phelps & McNamara. 1 June 2024
Biosimilars
Chief Executive Officers of the world’s largest generic and biosimilar medicines companies recently met in Vienna, Austria, to provide strategic advice to the International Generic and Biosimilar Medicines Association (IGBA). 29 May 2024
Pharmaceutical
French pharma trade group Leem (Les Entreprises du Medicament) has published its annual survey on the taxation of the pharmaceutical industry, compared to that of other European countries. 28 May 2024
Generics
UK-based Alliance Pharma (AIM: APH) has successfully appealed against a Competition and Markets Authority (CMA) ruling that had found the company guilty of breaching competition law. 24 May 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze